12:00 AM
Jul 21, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); MLL-AF9 fusion oncogene


INDICATION: Acute myelogenous leukemia (AML)

Cell culture and mouse studies suggest inhibiting MTHFD2 could help treat AML. In human AML cell lines, shRNA targeting MTHFD2 decreased proliferation and colony...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >